Compare Global X Autonomous & Electric Vehicles (DRIV) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Autonomous & Electric Vehicles vs Sanofi SA — how do they compare? Global X Autonomous & Electric Vehicles trades at $35.81, while Sanofi SA trades at $43.55 (market cap $104.30B). The key difference: Sanofi SA pays a 5.55% dividend while Global X Autonomous & Electric Vehicles pays none, and Global X Autonomous & Electric Vehicles is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| DRIV | SNY | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $42.53 | $52.34 |
52-Week Low | $25.23 | $41.33 |
Market Cap | — | $104.30B |
Enterprise Value | — | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DRIV trades at $36.14, up 1.6% today, with technical indicators showing a bullish trend supported by moving averages, though RSI suggests potential overbought conditions. The stock's support and resistance levels are tightly clustered around $35-$36. Recent news highlights strong global EV sales growth, particularly in Europe and China, driven by rising fuel prices and supportive policies, which may benefit DRIV's sector exposure.
The outlook for DRIV is positive due to favorable industry trends, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed, with technical strength offset by valuation concerns. Investors should weigh growth potential against execution risks in the evolving EV market.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
